These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3428009)

  • 1. In vitro evaluation of difloxacin (A-56619), A-56620, and other 4-quinolones against isolates from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1987; 33(6):419-27. PubMed ID: 3428009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of A-56619 (difloxacin) and A-56620, two aryl fluoroquinolones.
    Digranes A; Dibb WL
    Chemotherapy; 1988; 34(4):298-307. PubMed ID: 3208547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of difloxacin against canine bacterial isolates.
    van den Hoven R; Wagenaar JA; Walker RD
    J Vet Diagn Invest; 2000 May; 12(3):218-23. PubMed ID: 10826834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Bodey GP
    Antimicrob Agents Chemother; 1987 Jan; 31(1):102-3. PubMed ID: 3471177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patients.
    Rolston KV; LeBlanc B; Ho DH; Bodey GP
    J Antimicrob Chemother; 1990 Jul; 26(1):39-44. PubMed ID: 2211445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats.
    Boothe DM; Boeckh A; Simpson RB; Dubose K
    J Vet Intern Med; 2006; 20(6):1297-306. PubMed ID: 17186841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients.
    Rolston KV; LeBlanc B; Gooch G; Ho DH; Bodey GP
    J Antimicrob Chemother; 1989 Mar; 23(3):363-71. PubMed ID: 2732120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of PD127,391, a new quinolone against bacterial isolates from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1990; 36(5):365-72. PubMed ID: 2209169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria.
    Moros M; Coll R; Esteve M; Parés J; Xicota MA
    Chemioterapia; 1987 Jun; 6(2 Suppl):149-51. PubMed ID: 3509373
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro and in vivo evaluation of BMY 45243, a new 5-amino-naphthyridone derivative.
    Bouzard D; Di Cesare P; Hoffmann P; Fung-Tomc J; Kessler R
    Drugs Exp Clin Res; 1992; 18(7):291-4. PubMed ID: 1338310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.
    Hardy DJ; Swanson RN; Hensey DM; Ramer NR; Bower RR; Hanson CW; Chu DT; Fernandes PB
    Antimicrob Agents Chemother; 1987 Nov; 31(11):1768-74. PubMed ID: 3435123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative activities of clinafloxacin against gram-positive and -negative bacteria.
    Ednie LM; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 May; 42(5):1269-73. PubMed ID: 9593165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620 compared to that of other antimicrobial agents.
    Hirschhorn L; Neu HC
    Chemotherapy; 1987; 33(1):28-39. PubMed ID: 3549179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro evaluation of lomefloxacin].
    Dette GA; Knothe H
    Arzneimittelforschung; 1989 Aug; 39(8):832-5. PubMed ID: 2818672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of A-56619 and A-56620 against multi-resistant and routine clinical isolates.
    Fernandes CJ; Wilson RD; Ackerman VP
    Chemotherapy; 1988; 34(3):216-28. PubMed ID: 3416660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patients.
    Rolston K; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1988; 34(6):448-54. PubMed ID: 3149568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.